CD437-induced apoptosis has been investigated in NB4, a human t(15;17) acute promyelocytic leukemia (APL) cell line, and in the retinoic acid (RA)-resistant NB4-R1 derivative subclone. Both NB4 and NB4-R1 cells underwent rapid apoptosis in response to low doses of CD437 (10 −7 M). This apoptosis did not require the activation of classical retinoid receptors and like arsenic (As)-induced apoptosis was preceded by the rapid activation of a caspase-3-like enzymatic activity as indicated by the increase of DEVD-pNA hydrolytic activity, by the processing of procaspase-3 protein and by the cleavage of poly(ADP-ribose) polymerase (PARP). Furthermore, it was demonstrated that the caspase-3-like proteolytic activity is responsible for the degradation of both the PML/RAR␣ oncogenic protein and the normal RAR␣ proteins. In CD437-treated cells, PML proteins were not degraded and PML relocalization on PMLNBs occurred in all the cells before death. CD437-induced apoptosis and receptor degradation were proteasome independent and not influenced either by inhibitors of protein tyrosine kinases (PTK), protein tyrosine phosphatases (PTPases) and serine proteases or by glutathione levels. Moreover, our data suggested that as for As 2 O 3 -induced apoptosis Bc12 modulation is not significant for CD437-induced apoptosis of NB4 cells. Since CD437 induces in vitro the rapid apoptosis of both RA-sensitive and -resistant APL cells, it could represent the first retinoid potentially able to eradicate in vivo malignant leukemia blasts.
Introduction
Retinoids, structural analogues of vitamin A, are involved in a wide range of biological processes including cell differentiation, morphogenesis proliferation and antineoplastic activities. [1] [2] [3] [4] At the molecular level, retinoids bind to and activate specific nuclear receptors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs), which in turn, as homoor heterodimers, recognise specific DNA sequences regulating target gene expression. 3, 5, 6 It has been shown that retinoids also interfere with AP-1 transcription factors, leading to antiproliferative effects in tumor cells independent from the receptor-transactivating potential of retinoids. ration arrest by interfering either with RA or PML signals through the heterodimerization with PML as well as with RXRs. 10 On the other hand, results obtained with PML/RAR␣ transgenic mice have demonstrated the oncogenic properties of PML/RAR␣. [11] [12] [13] At cellular level, in the nucleus, PML/RAR␣ displaces PML from nuclear bodies structures (NBs) to illdefined microspeckled nuclear structures and since PML has growth suppressive properties, such loss of specific PML localization could antagonize its function. [14] [15] [16] [17] Remarkably, cell maturation of APL cells can be restored, to some extent, by retinoic acid treatment 18, 19 and a single course of RA is sufficient to cause clinical remission in APL patients. 20 RA treatment induces a progressive disappearance of the PML/RAR␣ microspeckles and restores the normal localization of PML on PML-NBs. 16 Concomitantly with the granulocytic maturation program and PML-NBs relocalization, RA promotes a proteasome-mediated degradation of PML/RAR␣ protein. 21 Another compound, arsenic trioxide (AS 2 O 3 ), at micromolar concentrations, is able to induce both partial maturation and total apoptosis of APL cells leading to the remission of the disease in patients. [22] [23] [24] As with RA treatment, AS 2 O 3 triggers PML/RAR␣ degradation and PML relocalization on PMLNBs. 25, 26 Since PML/RAR␣, as reported, could also work as a suppressor of apoptosis, 10, 27 these data suggest that either RA or AS 2 O 3 increase the ability of APL cells to undergo maturation and/or apoptosis through the down regulation of PML/RAR␣.
However, RA-induced maturation/apoptosis of APL cells is a slow process, which in patients causes short-lived remission followed by relapses which no longer respond to RA. 28 Furthermore, the isolation of spontaneous RA-resistant, 29 and arsenic-resistant NB4 sublines 26 suggests that relative longterm treatments with these drugs could select resistant clones in the cell population. Thus, it is of interest to develop new compounds which may be less toxic and more effective than RA or AS 2 O 3 either in maturation or apoptosis.
CD437, a RAR␥ selective synthetic retinoid, 30 has been reported to strongly inhibit in vitro cell proliferation and induce, in a dose-dependent manner, apoptosis in various human cell lines. [31] [32] [33] In human breast carcinoma cells and in the HL-60R leukemia cell line CD437 mediates its apoptotic action independently of RAR␥ expression through a RAR/RXRindependent pathway. 34, 35 Interestingly, CD437 also displays an antitumor activity in vivo against melanoma xenografts in nude mice 32 and causes apoptosis of ex vivo cultures of mouse thymocytes 36 or fresh human leukemic cells. 34 In this report, we analyze the properties of CD437 in the NB4 cell line. The NB4 cell line represents a unique model to study cell maturation and apoptosis in APL, since to date it is the only cell line with t(15;17) expressing chimeric PML/RAR␣ protein. 37 We show that CD437 is a potent inducer of apoptosis either in parental NB4 or in RA-resistant NB4-R1 cells. Similar to As 2 O 3 -induced apoptosis, CD437-induced apoptosis is associated with a rapid activation of caspase-3-like cysteine proteases, with the caspase-3-mediated proteolytic degradation of both PML/RAR␣ and RAR␣ proteins and also with the rapid PML retargeting on PML-NBs. Nevertheless, CD437 triggers the death of NB4 cell population in a shorter time compared to As 2 O 3 . Moreover, the degradation which affects PML/RAR␣, but not the PML proteins, is exclusively caspase-3 dependent and does not involve the proteasome-dependent pathway. Altogether, our results suggest that in NB4 cells CD437 activate a powerful specific pathway of cell death.
Materials and methods

Chemicals
Retinoids:
CD2019 and CD437 were synthesised by CIRD-Galderma (Sophia Antipolis, Valbonne, France) TTNPB, 38 Ro 41-5253 39 and Ro 61-8431 40 were kindly provided by Dr M Klaus, Hoffman-la Roche (Basel, Switzerland), SR 11237 was kindly provided by Dr H Gronemeyer. ATRA (all-trans retinoic acid) was purchased from Sigma-Aldrich (St Louis, MO, USA). For each compound a 10 −2 m stock solution in DMSO was prepared, the final concentration of DMSO in the culture medium never exceeded 0.1%.
Other compounds:
The calpain inhibitor N-acetylleucylleucylnorleucynal (LLnL), the serine protease inhibitor diisopropyl fluorophosphate (DFP), the protein tyrosine kinase (PTK) inhibitors genistein and erbstatin, the tyrosine phosphatase inhibitor phenylarsine oxide and the protein phosphatase inhibitor, okadaic acid, the protein kinase C (PKC) inhibitor cyclosporin A, N-acetylcysteine (NAC) and 1-buthionine-(S,R,)-sulfoximide (BSO) were from Sigma-Aldrich. The stable serine proteases inhibitor Pefabloc and the chymotrypsin-like protease inhibitor tosyl-l-phenylalanine chloromethyl ketone (TPCK) were from Bochringer Mannheim (Mannheim, Germany). The proteasome inhibitor lactacystin, the synthetic substrate of ced-3 (CPP32)-like caspases, Ac-DEVD-pNa and the synthetic substrate of ICE-like caspases, Ac-YVAD-pNA were from Biomol Research Lab (Plymouth Meeting, PA, USA). The synthetic inhibitor of ced-3/ICE family, z-VAD-fmk, the synthetic inhibitor of caspase-3 (ced-3) subfamily, Ac-DEVD-CHO and the synthetic inhibitor of caspase-1 (ICE) subfamily, Ac-YVAD-CHO were from Bachem Feinchemikalien (Budendorf, Switzerland). All drugs were prepared in DMSO except for lactacystin (10 
Cell culture conditions and induction of PML/RAR␣ degradation
The NB4 APL cell line and the NB4-derived lines NB4-R1 were kindly provided by M Lanotte. 29, 37, 41 The U937 MTPR9 cell line, which contains the PML/RAR␣ coding sequence under the control of the Zn 2+ -inducible mouse MT-1 promoter was obtained from PG Pelicci.
10 NB4, NB4-R1, HL-60, U937 and U937 MTPR9 cell lines were grown in RPMI-1640. Culture media were supplemented with 10% FCS (GIBCO-BRL, Gaithersburg, MD, USA). NB4 cell lines were grown under the same conditions as previously reported. 37 Generally, 4 × 10 5 /ml cells were pretreated for 30 min in the presence or absence of the various compounds and then incubated with the indicated concentrations of CD437.
Apoptosis and cell cycle distribution
DNA degradation was estimated by terminal deoxynucleotidyl transferase (TdT) labeling of DNA strand breaks. The tailing reaction, named TUNEL, was carried out according to the manufacturer's instructions (Boehringer Mannheim) except for a 4% formaldehyde fixation instead of a paraformaldehyde fixation. Cells were analyzed by fluorescence microscopy and by flow cytometry using a FACScan. All data were collected, stored and analyzed by LYSIS II software (Becton Dickinson, Sunnyvale, CA, USA). Cells were also analyzed for their DNA content and cell cycle distribution (CELLFIT cell cycle analysis; Becton Dickinson) by flow cytometry analysis of propidium iodine (PI)-stained nuclei. 42 
Immunofluorescence and Western blot analysis
Immunofluorescence was performed as previously described.
14 PML/RAR␣ and PML were revealed by rabbit polyclonal antibodies 14 followed by a FITC-labeled anti-rabbit polyclonal antibody (Serotec, UK). RAR␣ was revealed by a monoclonal antibody directed against the F region of RAR␣ (Ab9␣(F)) 43 (kindly provided by P Chambon (IGBMC, Strasbourg, France)) followed by a Texas red anti-mouse polyclonal antibody (Amersham, Aylesbury, UK). For Western blot analysis, cells were washed, resuspended in PBS, lysed in 1 × hot Läemmli sample buffer and boiled for 5 min. About 30 g of protein was analyzed on a 12% SDS-PAGE gel, and transferred to nitrocellulose by semi-dry blotting. For each gel CBB staining was used as quality control and protein quantitation on the gel. Transfer efficiency in each lane was assessed through Ponceau staining of nitrocellulose. Membranes were blocked with 10% skimmed milk in TBS-0.1% Tween for 1 h and incubated overnight with the following specific rabbit polyclonal antibodies: anti RAR␣ (RP␣FЈ) 43 (kindly provided by P Chambon) or anti-RAR␣ (C-20) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-PML, 14 anti-PARP (Biomol Research Lab, Plymouth Meeting, PA, USA), anti-CPP32 (Santa Cruz Biotechnology), anti p21 WAFI/CIP (Santa Cruz Biotechnology) as well as with anti-human Bcl-2 mouse monoclonal antibody (DAKO Corp, Carpinteria, CA, USA). Membranes were then incubated with anti-rabbit IgG or antimouse IgG horse radish peroxidase-conjugated antibodies (Biosys, Compiègne, France). Antibody complexes were detected by chemiluminescence with the ECL kit (Amersham). To estimate the apparent molecular mass of polypeptides, kaleidoscope prestained standards from BioRad were used (BioRad Laboratories, Richmond, CA, USA).
Assay of caspase activation
CPP32-like and ICE-like activities were measured, in the cytosol of cells treated with RA in the presence or absence of caspase inhibitors z-VAD-fmk, Ac-DEVD-CHO or Ac-YVAD-CHO, by an in vitro cleavage assay of the DEVD-pNA and YVAD-pNA colorimetric substrates, respectively. Cells were
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lysed at a density of 2 × 10 6 /ml in 10 mm Hepes pH 7.4, 2 mm EDTA, 0.1% CHAPS and 2 mm DTT. Assays were performed as previously described. 44 
Results
The synthetic retinoid CD437 induces a rapid apoptois in NB4 cells
Treatment of the APL-derivative NB4 cell line with CD437 resulted in a time-and dose-dependent decrease in cell number relative to control cultures. After treatment with 10 −7 m CD437, a decrease in the surviving cell fraction was observed as early as 6 h (80% viable), the loss of viability continuing in the following hours (50% at 24 h, 30% at 36 h) and almost all the cells died after 48 h (data not shown). Cell death was due to apoptosis as indicated by the formation of a DNA ladder in agarose gels (not shown) and by the appearance of fragmented and condensed nuclei in propidium iodine-stained or FITC-labeled cell preparations. A dose-response cytometric analysis following the application of the TUNEL assay indicated that a 10 −7 m CD437 treatment for 16 h was enough to induce 30% apoptosis, while 5 × 10 −7 m CD437 caused the total apoptosis of the cell population ( Figure 1 ). Apoptosis was also evident in the RA-resistant NB4-R1 cells cultured in the absence or presence of RA, suggesting that CD437-induced apoptosis is independent of both CD437 transactivation properties and RA-mediated differentiation ( Figure 1 ). This result corroborates previous data obtained with HL-60R cells.
34 CD437 was also apoptogenic in U937 cells; however, in these cells the kinetic of apoptotic induction was delayed
Figure 1
Apoptotic effects of CD437 on NB4 and NB4-R1 cells. NB4 cells were treated for 16 h with RA (all-trans) and CD437 concentrations indicated. NB4-R1 cells were cultivated in the absence or in the presence of 10 −6 m RA for 4 days, then treated for 16 h with the CD437 concentrations indicated. The percentage of apoptosis (%) was determined by flow cytometry analysis after a TUNEL assay. A representative experiment is shown.
compared to NB4 cells (50% apoptosis after 48 h of 10 −6 m CD437 treatment) (data not shown).
CD437 effects are independent of nuclear retinoid receptors
CD437 was originally developed as a RAR␥ selective agonist. 30 In NB4 cells, due to the absence of RAR␥ expression, the compound is devoid of cyto-differentiating activity 38 and it does not bind to or transactivate the RXRs. 35 Nevertheless, it is possible that its apoptotic activity is mediated by the activation of other RARs receptors or enhanced by the combination with either RAR or RXR-selective agonists. 45 CD437 was combined with either ATRA, TTNPB (a pan RAR agonist), CD2019 (a RAR␤ agonist) or SR11237 (a RXR agonist). Since specific agonists may transactivate other receptors at higher concentrations, the compounds were utilized at 10 −7 m and 10 −9 m (not shown) concentrations. At 16 h, the different combinations failed to exert any additive or synergistic effect on both the viability and apoptosis of NB4 cells (Table 1) . Furthermore, cotreatment with 10 −6 m Ro 41-5253 (a RAR␣ antagonist) or with 10 −6 m Ro 61-8431 (a pan RAR antagonist) also failed to prevent CD437-induced apoptosis, suggesting that the apoptogenic activity of the compound is not related to its ability to interact with classical retinoic acid receptors (Table 1) .
Biochemical characterization of the CD437 and As 2 O 3 apoptosis pathways: a comparative study
Caspases are aspartate-specific cysteine proteases that play a central role in the execution of the apoptotic program. 46 We have investigated the effect of inhibitors of different caspase specificities on CD437 and As 2 O 3 -induced apoptosis in NB4 cells. 10 −7 m CD437 promoted a rapid increase in DEVD-pNA hydrolytic activity without modifying YVAD-pNA hydrolytic activity. DEVD-pNA hydrolytic activity began to increase after NB4 cells (4 × 10 5 /ml) were treated for 16 h with 10 −7 M CD437, ATRA, TTNPB, CD2019, SR11237, or 10 −6 M Ro41-5253 and Ro61-8431, or with 10 −7 M CD437 in combination with each of the other compounds. At the end of the treatment, the number of cells and the viability was determined after Trypan blue staining. Each value represents the mean ± s.d. of three independent measures. Apoptosis (%) was determined after TUNEL assay, by flow cytometry. A representative experiment among three independent assays is presented.
Figure 2
Time course of DEVD-pNA hydrolytic activity. NB4 cells (500 000/ml) were treated with vehicle (DMSO, ), with 10 −6 m CD437 (᭜) or with 10 −6 m As 2 O 3 (b). Cell extracts were analyzed for DEVD-pNA hydrolytic activity and results are the mean ± s.d. of three separate cultures.
2 h of CD437 treatment ( Figure 2 ) and reached maximal levels at 16 h (Figure 2 ) when more than 30% of cells where apoptotic ( Table 2 ). Challenge of NB4 cells for 16 h with z-VADfmk (a general inhibitor of caspases), Ac-YVAD-CHO (a specific caspase-1 inhibitor) or with Ac-DEVD-CHO (a specific caspase-3 inhibitor) did not change the number of apoptotic cells in the cell population or the basal DEVD-pNA or YVADpNA hydrolytic activity. However, both z-VAD-fmk and Ac-DEVD-CHO completely blocked both the apoptotic effect and DEVD-pNA cleaving activity induced by CD437, while Ac-YVAD-CHO was completely ineffective (Table 2 ). These data
Figure 3
Western blot analysis of Bcl-2 and P21-expressions in NB4 cells. NB4 cells were treated for 16 h with medium alone, As 2 O 3 and CD437 as indicated. (a) The blot was probed with an anti-Bcl-2 specific antibody. The same membrane was first probed with an antip21 specific antibody (b) and then reprobed with an anti-actin specific antibody (c).
support the idea that CD437 causes activation of caspase-3 and/or caspase-3-like proteolytic activities which are probably responsible for both the appearance of DEVD-pNA hydrolytic activity in the cytosol of CD437-treated NB4 cells and the apoptotic process.
As 2 O 3 -induced apoptosis is a long-term process compared to CD437 effect. The total death of cell population takes 4-5 days. 26 10 −6 m As 2 O 3 promoted an increase of DEVD-pNA hydrolytic activity which became significant between 5 and 8 h. At 16 h, arsenic-induced apoptosis is lower than that observed in CD437-treated cells (Table 2) and DEVD-pNA hydrolytic activity corresponded to 1/3 of that induced by CD437 (Figure 2 ). Both z-VAD-fmk and Ac-DEVD-CHO partially blocked this apoptotic effect and totally blocked the DEVD-pNA hydrolytic activity. Also in this case, Ac-YVAD-CHO was ineffective in blocking both apoptosis and DEVDpNA hydrolysis (Table 2 ). These results suggest that, besides the caspase-3 activation, As 2 O 3 promoted a caspase-independent pathway of cell death.
Recent data show evidence of the link between proteasome function and programmed cell death. 47 In particular, in HL-60 cells, the treatment with proteasome inhibitors blocked proteasomal activity and activated programmed cell death in a dose-dependent manner. 48 Since short-term treatments with 10 −6 m lactacystin, 5 × 10 −5 m LLnL or with 50 g/ml TPCK had no cytotoxic effect in NB4 cells (Table 2) , we treated NB4 cells for 16 h with 10 −7 m CD437 or with 10 −6 m As 2 O 3 in the presence of these proteasome inhibitors. No additive or synergistic effect was evident, suggesting that proteasome activity is not involved in the apoptotic process ( Table 2) .
The redox status of cells is regulated, in part, by the presence of glutathione (GSH), by far the most abundant non-protein thiol in eukaryotic cells. 49 To examine the role of GSH on CD437-induced apoptosis, NB4 cells were treated with 10 −7 m CD437 or with 10 −6 m As 2 O 3 in the presence or absence of either 4 × 10 −2 m N-acetylcysteine (NAC) (an agent capable of elevating intracellular GSH) or with 10 −4 m buthionine-sulfoximide (BSO) (which inhibits glutamylcysteine synthetase, resulting in GSH depletion). Neither agent affected CD437-induced apoptosis (Table 2) suggesting that, the cascade of events required for CD437 apoptosis is not dependent on intracellular GSH levels. Interestingly, NAC blocked both As 2 O 3 -induced apoptosis and DEVD-pNA hydrolytic activity, suggesting as previously argued, 50 that glutathione is one important target of As 2 O 3 in the cell. Furthermore, these data indicate that in the As 2 O 3 apoptotic pathway the deregulation of glutathione levels occurs upstream of the caspases activation.
We have also examined the role of Bcl-2, a potent antagonist of apoptosis, in this process. Bcl-2 protein is highly expressed in NB4 and slowly down-regulated by RA.
26 NB4 cells treated with various concentrations of CD437 did not show any appreciable down-regulation of the protein ( Figure  3a) . Moreover, the analysis of cellular distribution of bcl-2 protein indicated that CD437 did not change the localization of bcl-2 in the cell; the protein was only recovered in the mitochondrial fraction (data not shown). These and other data indicate that Bcl-2 fails to protect NB4 cells from apoptosis induced by CD437. Contrary to CD437, As 2 O 3 induces the down-regulation of bcl-2 protein in NB4 cells (Figure 3a and Ref. 22 ) 22 but we have previously shown that the bcl-2 protein levels did not change during As 2 O 3 -induced apoptosis of NB4-R1. 26 A candidate gene which could play a critical role in CD437-induced apoptosis is p21 WAF1/CIP1 , p21, a cyclin-dependent kinase (cdk) inhibitor which blocks the cell cycle at both the G1/S and G2/M transitions during the apoptotic process after DNA damage. 52 It was demonstrated that p21 is transcriptionally activated by RA in U937 cells. 53 In fact, p21 was strongly up-regulated by either As 2 O 3 or RA in NB4 cells.
26 NB4 cells had a low baseline of p21 expression (Figure 3b ) and 16 h treatment of NB4 cells with 10 −6 m) As 2 O 3 up-regulated the p21 protein levels. Effective concentrations of CD437 (10 −7 m and 10 −6 m) did not modulate p21 expression (Figure 3b ). Altogether these results suggest that Bcl-2 and p21 WAF1/CIP1 modulations are not significant for CD437-induced apoptosis of NB4 cells.
Figure 5
Western blot analysis of CD437 effects on PML/RAR␣ and RAR␣ degradation. (a) Dose-response of PML/RAR␣ and RAR␣ degradation. The same filter utilized in Figure 3 was reprobed with an anti-RAR␣ specific antibody. (b) Time-course of PML/RAR␣ and RAR␣ degradation. NB4 cells were treated with 10 −7 m of ATRA and CD437 and cell extracts were subjected to Western blot analysis using first an anti-RAR␣ specific antibody and then an anti-actin specific antibody. (c) Effects of z-VAD-fmk on CD437-induced degradation. NB4 cells were treated overnight with medium, with 200 g/ml z-VAD-fmk or with 10 −7 m CD437 in the presence or M absence of 200 g/ml z-VAD-fmk. The filter was probed with an anti-RAR␣ specific antibody and then with an anti-actin specific antibody.
CD437 and As 2 O 3 promote the activation of caspase-3 (YAMA/CPP32)
PARP is a nuclear enzyme involved in DNA repair. 54 The cleavage of PARP abrogates its ability to repair the damaged or cleaved DNA in cells treated with an apoptotic stimulus. As shown in Figure 4a , treatment of NB4 cells for 6 h with CD437 resulted in a dose-dependent cleavage of the 116 kDa PARP protein. One of the products of this proteolytic cleavage is the 85 kDa fragment that contains the active site of the enzyme. 55 The formation of the 85 kDa product was observed as early as 4 h (data not shown) and 10 −7 m CD437 was enough to totally convert PARP in its degradative products (Figure 4a ).
Caspase-3 (YAMA/CPP32), a member of the caspase family of 10 or more aspartate-specific cysteine proteases, is primarily responsible for the cleavage of PARP during cell death. 55 Procaspase-3, when activated, is cleaved into two subunits of 17 and 12 kDa assembled into enzymatically active heterotetramers. 46 Figure 4b shows that the zymogen form of caspase-3 was partially cleaved in NB4 cells upon challenge with CD437. Caspase-3 activation and PARP cleavage correlates in a time-and in a dose-dependent manner: caspase-3 activation, like PARP cleavage, was evident at 4 h (not shown) and maximal after 16 h of CD437 induction. As for PARP cleavage, 10 −7 m CD437 caused the maximal activation of caspase-3 (Figure 4b ). CD437 treatment did not activate procaspase 1 (data not shown and Table 2 ). These results correlated with the data obtained with caspase inhibitors indicate that in NB4 cells, the caspase-3 family is principally involved in CD437-induced apoptosis. As expected, As 2 O 3 also caused loss of procaspase-3 and PARP cleavage beginning at 8 h (data not shown). At 16 h, when 10 −6 m As 2 O 3 produced complete PARP cleavage (Figure 4c ), procaspase-3, as seen with CD437, was only partially cleaved (Figure 4d ).
During CD437-induced apoptosis the caspase-3-like pathway triggers PML/RAR␣ degradation while PML relocalizes on PML-NBs
The proposed links between PML/RAR␣ expression and its anti-apoptotic activity 10, 26, 27 led us to study the fate of the fusion protein on NB4 cells treated with CD437. Western blot analysis using a RAR␣-specific antibody showed that effective concentrations (10 −7 m and more) of the compound caused the degradation of both PML/RAR␣ and, to a lesser extent, of RAR␣ proteins (Figure 5a ). The degradation began at 4 h (Figure 5b ), after caspase-3 activation, preceded the decrease of viability (detectable by Trypan blue exclusion) and was z-VAD-fmk sensitive (Figure 5c ). CD437 apoptosis and PML/RAR␣ degradation were not blocked by proteasome inhibitors (not shown) or by GSH depletion (Table 2 ). Since proteasome inhibitors blocked As 2 O 3 -induced degradation of PML/RAR␣ (Giannì et al, manuscript in preparation), this result suggest that CD437 bypasses the proteasome degradative pathway and rapidly activates the caspase degradative pathway responsible for the rapid proteolytic cleavage of this protein.
In APL cells, arsenic induces the targeting of nucleoplasmic PML to NBs coupled to PML degradation. 25 We analyzed the role of PML in CD437-induced apoptosis. Figure 6a shows that, at 16 h, effective concentrations (10 −7 m and more) of the compound did not influence the levels of PML proteins while 10 −6 m As 2 O 3 induced a total degradation of PML. Note that the polyclonal rabbit anti-PML antibodies weakly recognize the 120 kDa band which is likely to represent the PML/RAR␣ protein (absent in the HL-60 cell line) but it recognises very well the two other bands at 78 and 97 kDa representing PML proteins. 56, 57 The time of treatment did not change the levels (Figure 7b ). At 10 −7 m CD437, when the apoptosis of cells was already induced, a ratio of 50% of viable cells (characterized by a microspeckled staining) and 50% of apoptotic cells bearing one or two enlarged PML-NBs was observed (Figure 7c ). At 5 × 10 −7 m CD437, the number of speckled apoptotic cells increased (90%) but the few remaining viable cells always maintained the microspeckled pattern (Figure 7d ). The presence of red signals in apoptotic cells (Figure 7c and d) could represent a pool of RAR␣ immunoreactivity which does not colocalize with PML/RAR␣. In this respect, it is worth noting that in CD437-treated cells the PML/RAR␣ degradation preceded RAR␣ degradation (Figure 5a and b) and thus it is conceivable that a pool of RAR␣ was still present in apoptotic cells. At present we do not know the fate of RAR␣ during apoptogenesis, but since it is known that the levels of endogenous RAR␣ in NB4 cells is low, 15, 17 we can assume that RAR␣ concentrates itself in unknown nuclear structures. Alternatively, these red signals could represent technical artefacts due to the biochemical state of apoptotic cells. We never observed an intermediate microspeckled/speckled mixed pattern of immunofluorescence in the CD437-treated cell population. This was different from the one observed after As 2 O 3 treatment where the PML relocalization on PML-NBs was time-and dosedependent and occurred in all the cells before apoptosis commitment. 26 It is conceivable that in this case the rapid activation of caspases accelerated contemporaneously all events: PML/RAR␣ degradation, PML relocalization on PML-NBs and cell death. Taken together, these data and previous results 26 are consistent with the idea that PML/RAR␣ degradation favors apoptosis.
Discussion
In this report, we show that the RAR␥ synthetic retinoid CD437 is capable of inducing massive apoptosis in RA-sensitive or RA-resistant NB4 cells. As in other cellular models, the apoptogenic activity of CD437 is not mediated by retinoid receptors belonging to the family of RARs or RXRs. Interestingly, as in As 2 O 3 -triggered apoptosis, 26 treatment of NB4 cells with CD437 results in the degradation of PML/RAR␣ and in PML retargeting on NBs. However, CD437-induced apoptosis and degradation of receptor proteins is a very rapid process caused by caspase-3-like cysteine proteases or by other noncaspase proteases which might be activated downstream of caspases activation, 58 while As 2 O 3 -induced apoptosis and degradation of PML/RAR␣ is a relatively long process (M Giannì et al, manuscript in preparation). These results corroborate previous data establishing that beside the proteasome-dependent pathway of PML/RAR␣ degradation, 21 in APL cells, retinoids trigger its degradation through a caspase-mediated pathway. 59 At present, it is impossible to establish whether PML/RAR␣ degradation is a consequence or a cause of the apoptogenic process. Nevertheless, in both cases (As 2 O 3 and CD437), PML/RAR␣ degradation and PML relocalization on PML-NBs are concomitant or anticipate cellular death indicating, as previously argued, 26 that in APL cells, the PML/RAR␣ degradation could facilitate the full apoptotic response to these drugs. Contrary to As 2 O 3 , CD437 apoptosis a b c d
Figure 7
Confocal laser microscopy analysis of NB4 cells double-labeled with polyclonal anti-PML antibodies (revealed by FITC-labeled conjugate) and a monoclonal anti-RAR␣ antibody (revealed with a Texas red-labeled conjugate). NB4 were treated for 16 h with (a) medium, (b) 10 −8 m CD437, (c) 10
is not accompanied by a rapid PML degradation suggesting that the down-regulation of these proteins is not necessary for apoptosis. Conversely, the persistence of PML in apoptotic NB4 cells could be related to an active role of these proteins in cell death as mediators of apoptotic signals. 60, 61 Furthermore, since a caspase-3 cleavage site was mapped in the ␣-helix of PML, 59 our data suggest that this cleavage site is more accessible to caspases in PML/RAR␣ protein than in PML proteins.
As demonstrated by the increase of DEVD-pNA hydrolytic activity, by procaspase-3 decrease and PARP cleavage, CD437-induced apoptosis of NB4 cells is mediated by the subfamily of caspase-3 proteases. The procaspase-3 decrease most likely represents activation of the pre-existing proform by cleavage at aspartate residue and does not require a de novo protein synthesis. 46, 62, 63 The activation of multiple caspases, particularly caspases 3, 6 and 7, during drug-induced apoptosis in leukemia cells has been previously reported [64] [65] [66] and was also observed in CD437-treated NB4 cells (E Ponzanelli et al, manuscript in preparation) but the mechanisms through which CD437 induces caspases activation are still unknown. Pretreatment of NB4 cells with protein tyrosine kinase (PTK) inhibitors (genistein, erbstatin), protein kinase C (PKC) inhibitor (cyclosporin A), protein phosphatase inhibitors (phenylarsine oxide, okadaic acid) or serine proteases inhibitors (Pefabloc, DFP) does not influence CD437 apoptosis. Moreover, proteasome activity is not involved in this process as demonstrated by the inability of proteasome inhibitors (lactacystin, LLnL and TLCK) either to increase or prevent the apoptosis or block the PML/RAR␣ degradation induced by CD437.
Among the intracellular signals leading to caspase activation, the Bcl-2 expression has been proposed as a key function. 67 In fact, the expression of Bcl-2 blocked apoptosis in many tissues including the hemopoietic system and in particular, several reports suggested that the Bcl-2-mediated inhibition of cell death may involve an anti-oxidant pathway. 68, 69 However, results obtained in different cellular models suggested that Bcl-2 regulation per se is not significant for CD437-induced apoptosis 26, 31, 51 and As 2 O 3 -induced apoptosis. 26 As with the synthetic retinoid 4HPR, CD437 could generate a pro-oxidant activity implicated in its apoptotic potential. 70 However, NAC or BSO, two agents which altered GSH levels, were not able to influence CD437-induced apoptosis of NB4 cells (Table 2 ). Although this result does not exclude an increase of reactive oxygen species (ROS) mediated by other mechanisms, it strengthens previous data which exclude a pro-oxidant activity of CD437 31 and indicates that the mechanisms of apoptotic induction between the different retinoids are compound specific. Moreover, both the above results and the fact that CD437-induced apoptosis is refractory to expression of Bcl-2, correlates with previous reports which indicate that oxidative stress is not necessary for all types of programmed cell death. 71 On the contrary, As 2 O 3 -induced apoptosis was blocked by NAC suggesting that As 2 O 3 could alter glutathione levels. A decrease in the levels of glutathione could increase intracellular levels of ROS which predispose cells to DNA damage and successively activate caspase-3 like proteases.
It has already been demonstrated that CD437, concomitant with apoptosis, rapidly induces p21 in HL-60R, 34 in breast cancer cells 35 and in non-small-cell lung cancer (NSCLC) cell lines. 72 Thus, the marked increase of p21 in these cells could provide a likely explanation for the action of CD437 in inducing growth arrest and preventing cell cycle progression. We have also showed that p21 up-regulation is involved in As 2 O 3 -triggered apoptosis. 26 However, induction of apoptosis in NB4 cells and in C33A cells 31 by CD437 does not correlate with an up-regulation of p21 protein suggesting that the mechanisms mediating CD437 apoptotic effects are cell line-or cell-type dependent.
Altogether these results indicate that the CD437 apoptotic targets remain to be elucidated. Nevertheless, it was recently demonstrated that CD437 caused the rapid induction of c-Jun and AP-1 complexes into human lung cancer cell lines 72 and in human melanoma cells. 32 c-Jun, a component of the AP-1 complex involved in cell cycle progression, differentiation and cell transformation could also promote apoptosis in various cell types. [73] [74] [75] Interestingly, the analysis of the composition of AP-1 complexes induced by CD437 treatment indicated that the compound caused changes in the composition of AP-1 constituents. 32 These modifications could influence the transactivational potential of AP-1 complexes and seem to be implicated in the switching between proliferation and apoptosis. 32 Preliminary results indicated that in NB4 cells, CD437 also promoted an increase of AP-1 binding activity (M Giannì, unpublished results).
The ability of CD437 to induce even at low concentrations apoptosis in APL or in other leukemia cells 34 opens a new way in the therapeutic action of retinoids. By inducing rapid apoptosis, such retinoids could cause an irreversible eradication of the malignant clones both in RA-sensitive and in RAresistant APL relapses.
